SelO-mediated nicotinamide adenine dinucleotide hydrolysis and its implications for metabolic therapies

References

[1] Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD(+) metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol. 2021; 22(2): 119-141.

[2] Amjad S, Nisar S, Bhat AA, et al. Role of NAD(+) in regulating cellular and metabolic signaling pathways. Mol Metab. 2021; 49:101195.

[3] Stein LR, Imai S. The dynamic regulation of NAD metabolism in mitochondria. Trends Endocrinol Metab. 2012; 23(9): 420-428.

[4] Luongo TS, Eller JM, Lu MJ, et al. SLC25A51 is a mammalian mitochondrial NAD(+) transporter. Nature. 2020; 588(7836): 174-179.

[5] Jia X, Zhang T, Yang C, et al. NAD(+) hydrolysis catalyzed by SelO is required for mitochondrial homeostasis. Cell. 2026; 189(9): 2633-2647.e24.

[6] Sreelatha A, Yee SS, Lopez VA, et al. Protein AMPylation by an evolutionarily conserved pseudokinase. Cell. 2018; 175(3): 809-821.e19.

[7] Chen YF, Lin HC, Chuang KN, Lin CH, Yen HS, Yeang CH. A quantitative model for the rate-limiting process of UGA alternative assignments to stop and selenocysteine codons. PLoS Comput Biol. 2017; 13(2):e1005367.

[8] Freeberg KA, Udovich CC, Martens CR, Seals DR, Craighead DH. Dietary supplementation with NAD+-boosting compounds in humans: current knowledge and future directions. J Gerontol A Biol Sci Med Sci. 2023; 78(12): 2435-2448.

[9] Rajman L, Chwalek K, Sinclair DA. Therapeutic potential of NAD-boosting molecules: the in vivo evidence. Cell Metab. 2018; 27(3): 529-547.

Rights & permissions

2026 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.